Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study
- PMID: 36636092
- PMCID: PMC9830337
- DOI: 10.21037/jgo-22-1170
Gelatin sponge microparticles for transarterial chemoembolization combined with regorafenib in hepatocellular carcinoma: a single-center retrospective study
Abstract
Background: The treatment of advanced hepatocellular carcinoma (HCC) is challenging. The positive effect of gelatin sponge microparticles for transarterial chemoembolization (GSMs-TACE) in the treatment of Barcelona Clinic Liver Cancer (BCLC) stage C and large HCC has been confirmed by previous studies. This study initially explored the efficacy and safety of GSMs-TACE combined with regorafenib in patients with unresectable HCC who failed first-line sorafenib and/or lenvatinib therapy.
Methods: This retrospective study collated the data of patients who presented at the Affiliated Zhongshan Hospital of Dalian University between December 2018 and June 2021. Patients were treated with GSMs-TACE, followed by regorafenib 1 week later. Follow-up was conducted every 3 to 5 weeks after combination therapy. If the treatment was changed due to disease progression, the patients were followed up every 3 months to obtain overall survival (OS) time. The OS, progression-free survival (PFS), objective response rate (ORR) and disease control rate (DCR) was used to evaluate the efficacy of the treatment, while adverse events (AEs) was used to assess its safety.
Results: A total of 47 patients were included in the study. The age of patients was 64.4±6.8 years; There were 43 (91.5%) males and 4 (8.5%) females; the number of Child-Pugh grade A was 22 (46.8%) and B was 25 (53.2%); the longest tumor diameter was 5.1 cm [interquartile range (IQR), 3.8, 8.9 cm]; the number of BCLC grade B was 14 (29.8%) and grade C was 33 (70.2%). The median follow-up time was 11.6 months [95% confidence interval (CI): 10.8 to 14.0 months]. The median number of GSMS-TACE sessions was 3. The initial doses of regorafenib were 80 mg/d (n=17, 36.2%), 120 mg/d (n=23, 48.9%), and 160 mg/d (n=7, 14.9%). The median PFS was 6.0 months (95% CI: 4.5 to 7.5 months), and the median OS was 14.3 months (95% CI: 11.8 to 16.8 months). The ORR and DCR were 21.3% and 85.1%, respectively. The incidence of grade 3/4 AEs was 8 out of 47 patients (17.0%).
Conclusions: The study indicated that GSMs-TACE combined with regorafenib may be efficient and safe in patients with unresectable HCC. Future prospective large-scale studies should be conducted to verify these results.
Keywords: Gelatin sponge microparticles; hepatocellular carcinoma (HCC); regorafenib; transarterial chemoembolization.
2022 Journal of Gastrointestinal Oncology. All rights reserved.
Conflict of interest statement
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jgo.amegroups.com/article/view/10.21037/jgo-22-1170/coif). The authors have no conflicts of interest to declare.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9830337/bin/jgo-13-06-3183-f1.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9830337/bin/jgo-13-06-3183-f2.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/9830337/bin/jgo-13-06-3183-f3.gif)
Similar articles
-
Regorafenib combined with transarterial chemoembolization for unresectable hepatocellular carcinoma: a real-world study.BMC Gastroenterol. 2021 Oct 20;21(1):393. doi: 10.1186/s12876-021-01967-3. BMC Gastroenterol. 2021. PMID: 34670512 Free PMC article.
-
Transcatheter Arterial Chemoembolization With Gelatin Sponge Microparticles Treated for BCLC Stage B Hepatocellular Carcinoma: A Single Center Retrospective Study.Medicine (Baltimore). 2015 Dec;94(52):e2154. doi: 10.1097/MD.0000000000002154. Medicine (Baltimore). 2015. PMID: 26717358 Free PMC article.
-
Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.J Cancer Res Ther. 2017;13(5):767-772. doi: 10.4103/jcrt.JCRT_297_17. J Cancer Res Ther. 2017. PMID: 29237901
-
Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis.BMC Gastroenterol. 2018 Sep 4;18(1):138. doi: 10.1186/s12876-018-0849-0. BMC Gastroenterol. 2018. PMID: 30180810 Free PMC article. Review.
-
Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review.Front Oncol. 2022 Sep 28;12:980214. doi: 10.3389/fonc.2022.980214. eCollection 2022. Front Oncol. 2022. PMID: 36249023 Free PMC article. Review.
Cited by
-
Remote Loading: The Missing Piece for Achieving High Drug Payload and Rapid Release in Polymeric Microbubbles.Pharmaceutics. 2023 Oct 28;15(11):2550. doi: 10.3390/pharmaceutics15112550. Pharmaceutics. 2023. PMID: 38004529 Free PMC article.
References
-
- European Association for the Study of the Liver . Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236. Erratum in: J Hepatol. 2019 Apr;70(4):817. 10.1016/j.jhep.2018.03.019 - DOI - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous